Altimmune Statistics

Total Valuation

Altimmune has a market cap or net worth of GBP 424.96 million. The enterprise value is 282.14 million.

Market Cap	424.96M
Enterprise Value	282.14M

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	125.23M
Shares Outstanding	n/a
Shares Change (YoY)	+17.16%
Shares Change (QoQ)	+9.75%
Owned by Insiders (%)	0.69%
Owned by Institutions (%)	36.61%
Float	124.37M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	28,561.27
PB Ratio	3.08
P/TBV Ratio	3.08
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.52
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-5.71

Financial Position

The company has a current ratio of 17.18, with a Debt / Equity ratio of 0.09.

Current Ratio	17.18
Quick Ratio	16.83
Debt / Equity	0.09
Debt / EBITDA	n/a
Debt / FCF	-0.24
Interest Coverage	-118.87

Financial Efficiency

Return on equity (ROE) is -52.61% and return on invested capital (ROIC) is -33.59%.

Return on Equity (ROE)	-52.61%
Return on Assets (ROA)	-30.87%
Return on Invested Capital (ROIC)	-33.59%
Return on Capital Employed (ROCE)	-43.95%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	252
Profits Per Employee	-1.06M
Employee Count	59
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	-506,623
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -19.37% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-19.37%
50-Day Moving Average	6.95
200-Day Moving Average	7.02
Relative Strength Index (RSI)	47.41
Average Volume (20 Days)	3,287

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.95

Income Statement

In the last 12 months, Altimmune had revenue of GBP 14,879 and -62.43 million in losses. Loss per share was -0.79.

Revenue	14,879
Gross Profit	-50.43M
Operating Income	-67.30M
Pretax Income	-62.93M
Net Income	-62.43M
EBITDA	-67.21M
EBIT	-67.30M
Loss Per Share	-0.79

Full Income Statement

Balance Sheet

The company has 156.80 million in cash and 11.83 million in debt, with a net cash position of 144.97 million.

Cash & Cash Equivalents	156.80M
Total Debt	11.83M
Net Cash	144.97M
Net Cash Per Share	n/a
Equity (Book Value)	138.08M
Book Value Per Share	1.44
Working Capital	151.77M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -49.36 million and capital expenditures -7,439, giving a free cash flow of -49.37 million.

Operating Cash Flow	-49.36M
Capital Expenditures	-7,439
Free Cash Flow	-49.37M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-452,303.92%
Pretax Margin	-422,974.31%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Altimmune does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-17.16%
Shareholder Yield	-17.16%
Earnings Yield	-14.69%
FCF Yield	-11.62%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altimmune has an Altman Z-Score of 3.82 and a Piotroski F-Score of 2.

Altman Z-Score	3.82
Piotroski F-Score	2